Runben Biotechnology Co

Runben Biotechnology Co ROE

The Return on Equity (ROE) of Runben Biotechnology Co (603193.SS) as of Oct 14, 2026 is 14.16 %. In the previous year, Return on Equity (ROE) was 14.43 % — a change of -1.85% (lower).

ROE

14.16 %

YoY

-1.85%

Last updated:

In 2025, Runben Biotechnology Co's return on equity (ROE) was 14.16 %, a -1.85% increase from the 14.43 % ROE in the previous year.

The Runben Biotechnology Co ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
25.97 CNY
Jan 1, 2020
37.86 CNY
Jan 1, 2021
21.48 CNY
Jan 1, 2022
22.15 CNY
Jan 1, 2023
11.76 CNY
Jan 1, 2024
14.43 CNY
Jan 1, 2025
14.16 CNY
The Runben Biotechnology Co ROE history
YEARROEYoY
14.16 %-1.85%
14.43 %+22.64%
11.76 %-46.88%
22.15 %+3.11%
21.48 %-43.27%
37.86 %+45.80%
25.97 %—
Access this data via the Eulerpool API
Get Free API Key

Runben Biotechnology Co Stock analysis

What does Runben Biotechnology Co do? Runben Biotechnology Co is one of the most popular companies on Eulerpool.

ROE Details

Decoding Runben Biotechnology Co's Return on Equity (ROE)

Runben Biotechnology Co's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Runben Biotechnology Co's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Runben Biotechnology Co's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Runben Biotechnology Co’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Runben Biotechnology Co stock

Return on Equity (ROE) of Runben Biotechnology Co is 14.16 % in 2025.

Return on Equity (ROE) of Runben Biotechnology Co changed from 14.43 % to 14.16 %, representing a -1.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Runben Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Runben Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Runben Biotechnology Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Runben Biotechnology Co